Christa Krupski, DO, MPH, on Reinfusion of Tisagenlecleucel in B-ALL

“The main take home message is that CAR T-cell therapy reinfusion, if it does induce remission or re-induce B-cell aplasia, that window is very short. And it should only be used as a bridge to something like transplant, it will not be successful as a standalone or definitive therapy.”

Investigators from Cincinnati Children’s Hospital studied the use of tisagenlecleucel reinfusion in patients with relapsed B-cell acute lymphocytic leukemia and found that reinfusion did not induce favorable outcomes in these patients and may only have utility as a bridging therapy to other treatment options such as stem cell transplant. These data were presented by investigator Christa Krupski, DO, MPH, hematologist/oncologist, bone marrow transplantation, Cincinnati Children’s, at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19.

CGTLive spoke to Krupski to learn more about the need for this research and the questions that remain to be investigated with reinfusion of a chimeric antigen receptor (CAR) T-cell receptor therapy. She discussed the study conducted and the findings presented at the meeting, which included only short responses if any response in the study participants.

For more coverage of the 2023 Tandem Meetings, click here.

REFERENCE

Krupski C, Baggott C, McNerney KO, et al. Outcomes following tisagenlecleucel reinfusion in children and young adults with B-cell acute lymphocytic leukemia. Presented at: 2023 Tandem Meetings, February 15-18, Orlando, Florida. Late-breaker 4.